By Fineline Cube Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its HER2-targeting antibody-drug conjugate (ADC) trastuzumab rezetecan has received approval from China’s National Medical Products Administration (NMPA) for a third indication: the treatment of adult patients with HER2-positive colorectal cancer who have failed prior therapy with oxaliplatin, fluorouracil, and irinotecan.
Regulatory Milestone & Indication Expansion
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Product | Trastuzumab rezetecan (antibody-drug conjugate) |
| New Indication | HER2-positive colorectal cancer post-triple chemotherapy failure |
| Approval Date | August 7, 2026 |
| Total Approved Indications | 3 |
| Previous Approvals | • HER2-mutant NSCLC (post-systemic therapy) • HER2-positive breast cancer (post anti-HER2 therapy) |
Drug Mechanism & Innovation Profile
- Molecule Type: HER2-targeting antibody-drug conjugate (ADC)
- Development Status: Independently developed by Hengrui Pharmaceuticals
- Mechanism of Action: Binds to HER2-expressing tumor cells → internalization → protease cleavage in lysosome → payload release → cell cycle arrest → tumor cell apoptosis
- Target Population: Patients with limited treatment options after standard chemotherapy regimens
- Therapeutic Differentiation: Addresses unmet need in HER2-positive colorectal cancer, a molecularly-defined subset representing approximately 3-5% of all colorectal cancer cases
Clinical Significance & Market Impact
Colorectal cancer remains one of the leading causes of cancer mortality globally, with HER2-positive patients historically lacking targeted therapeutic options after progression on standard chemotherapy. The approval establishes trastuzumab rezetecan as the first HER2-directed ADC approved specifically for this indication in China, offering a precision medicine approach for a molecularly-defined patient population.
With three distinct tumor type approvals, trastuzumab rezetecan demonstrates Hengrui’s successful execution of a tumor-agnostic development strategy targeting HER2 alterations across multiple solid tumor indications. This multi-indication approach significantly expands the drug’s addressable market and reinforces Hengrui’s position as a leader in China’s ADC development landscape.
Strategic Commercial Outlook
- Addressable Population: Estimated 15,000-20,000 annual HER2-positive colorectal cancer cases in China
- Competitive Advantage: First-mover advantage in HER2-positive colorectal cancer ADC space
- Revenue Diversification: Third indication substantially increases peak sales potential beyond initial breast cancer and NSCLC markets
- Global Potential: Strong foundation for international regulatory submissions based on robust clinical data across multiple tumor types
- Pipeline Synergy: Validates Hengrui’s ADC platform technology for future pipeline candidates
Forward-Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, market potential, and commercial expectations for trastuzumab rezetecan. Actual results may differ due to risks including market adoption rates, competitive dynamics, pricing pressures, and international regulatory requirements.-Fineline Info & Tech